Skip to main content

Advertisement

SpringerLink
Log in

Interleukin-8 and nuclear factor kappa B are increased and positively correlated in myelodysplastic syndrome

  • Short Communication
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The pathogenesis of myelodysplastic syndromes (MDS) is complex and depends on the interaction between aberrant hematopoietic cells and their microenvironment, probably including aberrations in cytokines and their signaling pathways. To evaluate interleukin-8 (IL-8) plasma levels and nuclear factor kappa B (NF-kB) in patients with MDS and to test possible correlation between IL-8 and NF-Kb, a total of 45 individuals were analyzed: 25 consecutive adult de novo MDS patients and 20 sex and age-matched healthy elderly volunteers. IL-8 analysis was performed by ELISA and activity of NF-kB by chemiluminescent assay. MDS patients showed higher level of IL-8 when compared to controls (p = 0.006). Patients aged 75 and above showed even higher levels (p = 0.035). NF-kB activity was significantly elevated in MDS patients when compared to controls (p < 0.0001) and higher in patients older than 75 years (p = 0.047). NF-kB activity was associated with higher serum ferritin (p = 0.042) and higher percentage of blasts (p = 0.028). A significant positive correlation between IL-8 and NF-kB was demonstrated (r = 0.480; p = 0.015). Many pathways involved in pathophysiology of MDS have been recently described, suggesting that an inflammatory process may act as a pathogenic driver. In this study, significantly elevated levels of IL-8 and NF-kB were demonstrated in MDS patients, with positive association of NF-kB with some markers of poor prognosis. A positive correlation between IL-8 and NF-kB suggests they cooperate as part of a complex networking of immune and inflammatory factors involved in MDS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: contemporary review. Am J Hematol. 2016;91:76–89.

    Article  CAS  PubMed  Google Scholar 

  2. Magalhaes SMM, Madeira TS, Bittencourt R, Velloso E, de Lourdes Chauffaille M, Azevedo AA, et al. Epidemiological and clinicopathological data from the Brazilian registry of patients with myelodysplastic syndromes and comparative analysis between different geographic areas. Blood. 2010;116(21):1884.

    Google Scholar 

  3. Magalhães SMM, Heredia FF, Fernandes LC, Sousa J, Almeida PJ, Souza GF, et al. Beyond race-related disparities: is myelodysplastic syndrome the same everywhere? Leuk Lymphoma. 2013;54:1564–6.

    Article  PubMed  Google Scholar 

  4. Belli CB, Pinheiro RF, Bestach Y, et al. Myelodysplastic syndromes in South America: a multinational study of 1080 patients. Am J Hematol. 2015;90:851–8.

    Article  CAS  PubMed  Google Scholar 

  5. Gañán-Gómez I, Wei Y, Starczynowski DT, et al. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia. 2015;29:1458–69.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Zahid MF, Patnaik MM, Gangat N, et al. Insight into the molecular pathophysiology of myelodysplastic syndromes. Eur J Haematol. 2016;97:313–20. doi:10.1111/ejh.12771.

    Article  CAS  PubMed  Google Scholar 

  7. GlenthØj A, Ørskov AD, Hansen JW, Sine RH, O’Connell C, Grønbæk K. Immune mechanisms in myelodysplastic syndrome. Int J Mol Sci. 2016;17:944.

    Article  PubMed Central  Google Scholar 

  8. Wolach O, Stone R. Autoimmunity and inflammation in myelodysplastic syndromes. Acta Haematol. 2016;136:108–17.

    Article  CAS  PubMed  Google Scholar 

  9. Shahzad A, Knapp M, Lang I. Interleukin-8: a universal biomarker? Int Arch Med. 2010;3:11.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Waugh DJJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14:6735–41.

    Article  CAS  PubMed  Google Scholar 

  11. Schinke C, Giricz O, Li WL, et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood. 2015;125:3144–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kornblau SM, McCue D, Singh N, et al. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood. 2010;116:4251–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Singh J, Simões BM, Howell SJ, et al. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 2013;15:210.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Zhang M, Fanf T, Wang K, et al. Association of polymorphisms in interleukin-8 gene with cancer risk: a meta-analysis of 22 case–control studies. Onco Targets Therapy. 2016;9:3727–37.

    Article  Google Scholar 

  15. Aggarwal BB. Nuclear factor-kB: the enemy within. Cancer Cell. 2004;6:203–8.

    Article  CAS  PubMed  Google Scholar 

  16. Braun T, Carvalho G, Coquelle A, et al. NFkB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood. 2006;107:1156–65.

    Article  CAS  PubMed  Google Scholar 

  17. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kB as the matchmaker. Nat Immunol. 2011;12(8):715–23.

    Article  CAS  PubMed  Google Scholar 

  18. Gilmore TD. Introduction to NF-kB: players, pathways, perspectives. Oncogene. 2006;25:6680–4.

    Article  CAS  PubMed  Google Scholar 

  19. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.

    Article  CAS  PubMed  Google Scholar 

  21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.

    Article  CAS  PubMed  Google Scholar 

  22. Flülöp T, Dupuis G, Witkowski JM, et al. The role of immunosenescence in the development of age-related diseases. Rev Invest Clin. 2016;68:84–91.

    Google Scholar 

  23. Meyers CA, Albitar M, Estey E. Cognitive impairment fatigue and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104:788–93.

    Article  CAS  PubMed  Google Scholar 

  24. He Q, Liu F. Unexpected role of inflammatory signaling in hematopoietic stem cell development: its role beyond inflammation. Curr Opin Hematol. 2016;23:18–22.

    Article  CAS  PubMed  Google Scholar 

  25. Porter JB, Garbowski M. The pathophysiology of transfusional iron overload. Hematol Oncol Clin N Am. 2014;28:683–701.

    Article  Google Scholar 

  26. Banerjee A, Mifsud NA, Bird R, et al. The oral iron chelator deferasirox inhibits NF-kB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anemia. Br J Haematol. 2015;168:576–82.

    Article  CAS  PubMed  Google Scholar 

  27. Yang L, Qian Y, Eksioglu E, et al. The inflammatory microenvironment in MDS. Cell Mol Life Sci. 2015;72:1959–66.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was conducted with partial support from National Counsel of Technological and Scientific Development (CNPq) and Cearense Foundation for the Support of Scientific and Technological Development (FUNCAP).

Author information

Authors and Affiliations

  1. Cancer Cytogenomic Laboratory, Federal University of Ceará, Fortaleza, Brazil

    Anacélia Gomes de Matos, Howard Lopes Ribeiro Junior, Daniela de Paula Borges, Bruno Memória Okubo, Juliana Cordeiro de Sousa, Ronald Feitosa Pinheiro & Silvia Maria Meira Magalhães

  2. Post-graduate Program in Medical Science, Federal University of Ceará, Fortaleza, Brazil

    Anacélia Gomes de Matos, Howard Lopes Ribeiro Junior, Daniela de Paula Borges, Bruno Memória Okubo, Juliana Cordeiro de Sousa, Ronald Feitosa Pinheiro & Silvia Maria Meira Magalhães

  3. Department of Clinical Medicine, Federal University of Ceará, Fortaleza, Brazil

    Ronald Feitosa Pinheiro & Silvia Maria Meira Magalhães

  4. Department of Clinical and Toxicological Analysis, Federal University of Ceará, Fortaleza, Brazil

    Maritza Cavalcante Barbosa, Marilena Facundo de Castro & Romélia Pinheiro Gonçalves

  5. Center for Research and Drug Development (NPDM), Federal University of Ceará, R. Coronel Nunes de Melo, 1000 - 2° andar, Rodolfo Teófilo, Fortaleza, CE, CEP 60430-275, Brazil

    Anacélia Gomes de Matos, Howard Lopes Ribeiro Junior, Daniela de Paula Borges, Ronald Feitosa Pinheiro & Silvia Maria Meira Magalhães

Authors
  1. Anacélia Gomes de Matos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Howard Lopes Ribeiro Junior
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniela de Paula Borges
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bruno Memória Okubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Juliana Cordeiro de Sousa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maritza Cavalcante Barbosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marilena Facundo de Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Romélia Pinheiro Gonçalves
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ronald Feitosa Pinheiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Silvia Maria Meira Magalhães
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AGM, HLRJ, DPB, BMO, JCS, MCB, MFC, RPG, RFP and SMMM designed the study, provided patient materials and were responsible for collection and assembly of data. All drafted and edited the manuscript. All authors have approved the final version of manuscript before publication.

Corresponding author

Correspondence to Ronald Feitosa Pinheiro.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest.

Ethical approval

This study was approved by Committee of Ethics in Research with Human Beings of Walter Cantídio University Hospital/Federal University of Ceara (#1.359.984).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de Matos, A.G., Ribeiro Junior, H.L., de Paula Borges, D. et al. Interleukin-8 and nuclear factor kappa B are increased and positively correlated in myelodysplastic syndrome. Med Oncol 34, 168 (2017). https://doi.org/10.1007/s12032-017-1023-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-017-1023-1

Keywords

Search

Navigation